methyl 5-oxo-1-(p-tolyl)pyrrolidine-3-carboxylate | 133747-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: methyl 5-oxo-1-(p-tolyl)pyrrolidine-3-carboxylate
• 英文别名: 5-oxo-1-p-tolylpyrrolidine-3-carboxylic acid methyl ester；Methyl 1-(4-tolyl)-5-oxo-3-pyrrolidinecarboxylate；Methyl 1-(4-methylphenyl)-5-oxopyrrolidine-3-carboxylate
• CAS: 133747-58-7
• 化学式: C₁₃H₁₅NO₃
• 分子量: 233.267
• InChiKey: TVSDUAUFGOYHLR-UHFFFAOYSA-N

物化性质

• 沸点：
  434.1±45.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 5-oxo-1-(p-tolyl)pyrrolidine-3-carboxylate 在 盐酸 、 一水合肼 作用下， 以 水 、 异丙醇 为溶剂， 反应 4.0h， 生成 1-(4-methylphenyl)-5-oxo-N'-(4-oxo-1,4-dihydronaphthalen-1-ylidene)pyrrolidine-3-carbohydrazide
  参考文献：
  名称：

  5-氧代-1-苯基吡咯烷-3-碳酰肼与1,4-萘醌衍生物的反应及所得产物的性质

  摘要：

  N '-（4-Oxo-1,4-二氢萘-1-亚甲基）-1-苯基-5-氧吡咯烷-3-碳酰肼和N '-（3-甲基-4-氧代-1,4-二氢萘-1 -亚苯基）-1-苯基-5-氧吡咯烷-3-碳酰肼通过5-氧代-1-苯基吡咯烷-3-碳酰肼与1,4-萘醌或2-甲基-1,4-萘醌的反应合成。使用碘乙烷获得上述产物的烷基化类似物。5-氧代-1-苯基吡咯烷-3-碳酰肼与2,3-二氯-1,4-萘醌的相互作用随后形成N '-（3-氯-1,4-二氧代-1,4-二氢萘-2-基）-1-苯基-5-氧吡咯烷-3-碳酰肼。所有这些化合物的特征均使用1 H，1313 C NMR，IR和质谱。测试了一些新化合物的抗微生物和抗真菌活性。

  DOI：

  10.1007/s11164-011-0306-y
• 作为产物：
  描述：

  衣康酸 在 硫酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 21.0h， 生成 methyl 5-oxo-1-(p-tolyl)pyrrolidine-3-carboxylate
  参考文献：
  名称：

  [EN] AUTOTAXIN INHIBITORS
  [FR] INHIBITEURS DE L'AUTOTAXINE

  摘要：

  本发明涉及如下式（I）的化合物：其中R1、R2、R3、R4a、R4b、R4C、R4d、L、A、Q、W和HET分别如本文所定义。本发明的化合物是自体脂肪酶（ATX）酶活性的抑制剂。本发明还涉及制备这些化合物的方法，包括含有它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及ATX活性有所涉及的其他疾病或情况（如纤维化）中的用途。

  公开号：

  WO2016124938A1

文献信息

• Phenylcarboxylic acid derivatives having hetero ring
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：US05145865A1

  公开（公告）日：1992-09-08

  Phenylcarboxylic acid derivatives having a hetero ring in the substituent of the formula: ##STR1## wherein R.sup.1 is halogen, alkyl, cycloalkyl, hydroxy, alkoxy, phenoxy which has a substituent selected from halogen and alkyl, carboxyl, alkylsulfonyloxy, phenylsulfonyloxy optionally substituted by halogen, alkylsulfonyloxyalkoxy, amino, alkanoylamino, benzoylamino, alkenyloxy, phenylalkoxyalkoxy, hydroxyalkoxy, phenylalkoxy having optionally 1 to 3 substituents selected from halogen, alkyl and alkoxy, halogenoalkyl, cycloalkyloxy optionally substituted by hydroxy, alkoxy substituted by cycloalkyl having optionally hydroxy substituent, imidazolylalkyl or imidazolylalkoxy; k is 0 or 1 to 3; or (R.sup.1).sub.k is alkylenedioxy; A is alkylene or alkylenoxy; l is 0 or 1; B is methylene or carbonyl; m is 0 or 1; D is alkylene; E is alkylene or alkenylene; n is 0 or 1; and R.sup.2 is hydrogen or alkyl, or a salt thereof, which have fatty acid synthesis-inhibitory activity, cholesterol synthesis-inhibitory activity and are useful as antilipidemic agent, prophylactic and treating agent of arteriosclerosis, prophylactic and treating agent of obesity, antidiabetics.

  具有杂环取代基的苯甲酸衍生物的化学式：其中R.sup.1是卤素、烷基、环烷基、羟基、烷氧基、苯氧基，其取代基可选择自卤素和烷基、羧基、烷基磺酰氧基、苯基磺酰氧基，可选择地取代为卤素、烷基磺酰氧基烷氧基、氨基、烷酰胺基、苯甲酰胺基、烯烃氧基、苯基烷氧基烷氧基、羟基烷氧基、苯基烷氧基，其可选择地具有1至3个取代基，选自卤素、烷基和烷氧基、卤代烷基、环烷氧基，可选择地取代为羟基，烷氧基取代为环烷基，其可选择地具有羟基取代基，咪唑基烷基或咪唑基烷氧基；k为0或1至3；或（R.sup.1）.sub.k为亚烷二氧基；A为烷基或烷氧基；l为0或1；B为亚甲基或羰基；m为0或1；D为烷基；E为烷基或烯基；n为0或1；R.sup.2为氢或烷基，或其盐，具有脂肪酸合成抑制活性、胆固醇合成抑制活性并用作抗血脂药物、动脉粥样硬化的预防和治疗药物、肥胖症的预防和治疗药物、抗糖尿病药物。
• Efficient novel eutectic-mixture-mediated synthesis of benzoxazole-linked pyrrolidin-2-one heterocycles
  作者：Yassine Riadi、Oussama Ouerghi、Mohammed H. Geesi、Abdellah Kaiba、El Hassane Anouar、Philippe Guionneau

  DOI：10.1016/j.molliq.2020.115011

  日期：2021.2

  infrared spectroscopy were employed to investigate the structure of the ionic liquid and characterize the DES, respectively. This method exhibited key advantages of high productivity, a short reaction time, and simple processing. Moreover, this DES was easily separated from reaction mixtures and can be recycled for multiple reactions.

  在这项研究中，在新设计的无金属深共熔溶剂（DES）的存在下，采用取代的苄胺和2-氨基苯酚，通过生态高效策略合成了新的苯并恶唑连接的吡咯烷酮杂环化合物。通过使用尿素和合成的甘氨酸衍生的离子液体的低共熔混合物来制备该DES。X射线衍射和红外光谱法分别用于研究离子液体的结构和表征DES。 该方法显示出高生产率，短反应时间和简单加工的主要优点。此外，该DES易于从反应混合物中分离出来，并可循环用于多个反应。
• Autotaxin inhibitors
  申请人：CANCER RESEARCH TECHNOLOGY LIMITED

  公开号：US10428061B2

  公开（公告）日：2019-10-01

  The present invention relates to compounds of formula I wherein R1, R2, R3, R4a, R4b, R4c, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

  本发明涉及式 I 的化合物 其中 R1、R2、R3、R4a、R4b、R4c、R4d、L、A、Q、W 和 HET 各如本文所定义。本发明的化合物是自旋共振素（ATX）酶活性的抑制剂。本发明还涉及这些化合物的制备工艺、含有这些化合物的药物组合物，以及它们在治疗增殖性疾病（如癌症）和其他涉及 ATX 活性的疾病或病症（如纤维化）中的用途。
• Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses
  作者：S Watanabe、K Ogawa、T Ohmo、S Yano、H Yamada、T Shirasaka

  DOI：10.1016/0223-5234(94)90029-9

  日期：1994.1

  The synthesis of a series of 4[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits in vivo, are described. Among the compounds synthesized, 7e, 7g, 7h, 7i, 7k, 7r, 21, 23 and 29a b showed a potent inhibitory activity toward fatty-acid and sterol biosyntheses. Their IC(50)s were 4.4-6.8 x 10(-6) M and 6.6-9.8 x 10(-6) M, respectively. These activities were always superior to those of compounds I, II, III and Clinofibrate as references. The inhibitory activity toward the sterol biosynthesis of these compounds was inferior to that of Pravastatin. The reducing effects of the representative compounds (7e and 7l) toward plasma cholesterols and triglyceride were evaluated in Japanese white rabbits (30 and 100 mg/kg, po) and compared with those of Clinofibrate:and Pravastatin; The compounds showed a similar hypocholesterolemic effect to Pravastatin and a more potent hypotriglycemic effect than Clinofibrate and Pravastatin in this animal model. Thus, a dual,action of hypolipidemic effects was noted in 7e and 7l compared with the references.
• Phenylcarboxylic acid derivatives having a hetero ring
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0393607B1

  公开（公告）日：1996-02-21